跳转至内容
Merck
CN

1672206

USP

托吡酯

United States Pharmacopeia (USP) Reference Standard

别名:

2,3: 双-4,5-O-（1-甲基亚乙基）-36--D -吡喃果糖氨基磺酸酯, McN 4853, RWJ 17021, 妥泰

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C12H21NO8S
化学文摘社编号:
97240-79-4
分子量:
339.36
NACRES:
NA.24
PubChem Substance ID:
329751353
UNSPSC Code:
41116107
MDL number:
MFCD00865320

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

托吡酯, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

SMILES string

NS(OC[C@]12[C@](OC(C)(C)O2)([H])[C@@]3([H])[C@@](OC(C)(C)O3)([H])CO1)(=O)=O

InChI key

KJADKKWYZYXHBB-XBWDGYHZSA-N

grade

pharmaceutical primary standard

API family

topiramate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... CA2(760), CA4(762), GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879), GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893), GRIK1(2897), GRIK2(2898), GRIK3(2899), GRIK4(2900), GRIK5(2901), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

正在寻找类似产品? 访问 产品对比指南

相关类别

Biochem/physiol Actions

红藻氨酸 GluR5 受体拮抗剂；抗惊厥药。

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Topiramate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Topiramate Capsules
  • Topiramate Tablets
  • Topiramate Compounded Oral Suspension
Topiramate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Topiramate Tablets
  • Topiramate Compounded Oral Suspension

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Topiramate
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 42(6), 4429-4429 (2020)
Topiramate Compounded Oral Suspension
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(4), 4436-4436 (2014)
Topiramate Capsules
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(1), 4432-4432 (2020)
Topiramate Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 34(5), 4434-4434 (2020)
Elizabeth M Kelly et al.
Journal of managed care pharmacy : JMCP, 19(8), 642-654 (2013-10-01)
Obesity may lead to the development of multiple chronic disease states, including hypertension, dyslipidemia, and type 2 diabetes mellitus. Over a half billion adults worldwide are affected by obesity, and more than two-thirds of adults are either obese or overweight
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持